معرفی
Professor Michael Cowley is a Research Professor and Chairman in the Department of Physiology at Monash University, affiliated with the Monash Biomedicine Discovery Institute and the Victorian Heart Institute. He has held a key academic and leadership role since 2008 and is a prominent figure in metabolic and neuroendocrine research.
Research Interests: His work centers on understanding the mechanisms of obesity, diabetes, and metabolic disorders, particularly focusing on leptin resistance, the melanocortin system, insulin sensitivity, and the neural regulation of metabolism. His research has direct translational applications in developing novel therapeutics for obesity, type 2 diabetes, obesity-induced heart disease, and polycystic ovarian syndrome.
The recent articles highlight a consistent focus on neuroendocrine control of metabolism, leptin signaling pathways, inflammation in obesity, and the development of pharmacological interventions. Key themes include the role of hypothalamic enzymes in metabolic resistance, the melanocortin pathway in energy balance, and the cardiometabolic effects of combination drug therapies.
Scientific Awards:
- VESKI Innovation Fellowship (2008)
- Science Ministers Prize for Australian Life Scientist of the Year (2009)
- High Blood Pressure Research Council of Australia Austin Doyle Lectureship (2009)
- WISDEM Lecture, UK (2009)
- Pfizer Australia Senior Research Fellowship (2009–2014)
- Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE) (2011)
- Inaugural Jacques Miller Medal for Experimental Biomedicine (2014)
Advising and Grants: While specific student names are not listed, Professor Cowley leads major research projects as a Primary Chief Investigator, including ongoing studies on glucose control in type 1 diabetes, central insulin resistance, and novel therapeutic development. His grant portfolio includes funding from JDRF and other national and international sources, reflecting sustained research activity and leadership.
Labs and Teams: He founded and directed the Monash Obesity & Diabetes Institute (MODI) and continues to lead research through the Department of Physiology and the Biomedicine Discovery Institute. His work involves collaboration with industry and clinical partners, exemplified by spin-out companies such as Orexigen Therapeutics and ReverX.
